論文・技術情報追加のお知らせ

1. Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system.

新生児の副作用報告が不足しており、改善が必要

対象DB：FAERS

2. Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system.

ロルラチニブの安全性プロファイルをFAERSデータで解析

対象DB：FAERS

3. Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data.

ボセンタンとマシテンタンに肝障害のリスクが確認され注意が必要

対象DB：FAERS

4. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.

バルベナジンで新たな神経系副作用が認識され注意が必要

対象DB：FAERS

5. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database.

ラスミジタン使用で神経系障害のリスクに注意が必要

対象DB：FAERS

6. Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report.

CAR-T細胞治療後にアナフィラキシー発生の可能性があることを示唆

対象DB：FAERS

7. Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database.

リバーロキサバンは出血リスク、アピキサバンは死亡や心臓・脳のリスク、エドキサバンは腎・尿路リスクが高い

対象DB：FAERS

8. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system.

セマグルチドは投与経路により副作用が異なるため注意が必要

対象DB：FAERS

9. The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).

ケタミンとエスケタミンの自殺企図リスクは低いが、注意が必要

対象DB：FAERS

10. A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.

セフロキシムの副作用は投与方法で異なり注意が必要

対象DB：FAERS

11. A pharmacovigilance study of FDA adverse events for sugammadex.

スガマデクスは予期しない重篤な副作用があり注意が必要

対象DB：EudraVigilance,FAERS

12. Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.

テプロツムマブは耳や内耳、代謝、消化器系に重大な副作用の可能性あり

対象DB：FAERS

13. Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study.

ALK阻害剤とてんかんの関連性をFAERSで調査

対象DB：FAERS

14. Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance.

妊娠中のADRを特定する新アルゴリズムが有効

対象DB：EudraVigilance

15. Omeprazole and Risk of Hypertension: Analysis of Existing Literature and the WHO Global Pharmacovigilance Database.

オメプラゾールは高血圧を引き起こす可能性

対象DB：VigiBase

16. Comparison of Endovascular Therapy and Open Surgical Revascularization in Patients With Acute Superior Mesenteric Artery Occlusion: A Large-Scale Analysis Based on the JROAD-DPC Database.

急性腸間膜虚血のEVTとOSの治療成績は同等

対象DB：DPC

17. Joint associations of air pollutants during pregnancy, infancy, and childhood with childhood persistent asthma: Nationwide database study in Japan.

低レベルの大気汚染が小児喘息リスクを増加

対象DB：JMDC

18. Could primary care records be used to identify women at risk of perinatal anxiety? A mixed-methods study.

PNAリスク特定は可能だが記録に無い要因も存在

対象DB：CPRD

19. Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study.

IPF患者はCOPD患者や対照群に比べ併存疾患が多く、死亡率も高い

対象DB：CPRD

20. Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study.

IBD患者のインフルワクチン接種率は低く、発症予防が推奨

対象DB：CPRD

21. Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET).

ONTARGET試験結果は過小評価群にも適用可能

対象DB：CPRD

22. The Impact of the COVID-19 Pandemic on Incidence and Short-Term Survival for Common Solid Tumours in the United Kingdom: A Cohort Analysis.

パンデミックで多くの癌の短期生存率が低下

対象DB：CPRD

23. Age-Dependent Relationship of Physical Inactivity with Incident Cardiovascular Disease: Analysis of a Large Japanese Cohort.

高齢者ほど身体活動不足が心血管疾患リスクを高める

対象DB：DeSC